UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares EPIX Nasdaq Capital Market ESSA ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1250 ...

Financial Performance - Net loss for the period before taxes was $10,854,604 for the three months ended March 31, 2022, compared to a loss of $12,965,247 for the same period in 2021, indicating an improvement of about 16.3%[28] - Basic and diluted loss per common share improved from $(0.36) in Q1 2021 to $(0.25) in Q1 2022[28] - The company reported a comprehensive loss of $10,903,335 for the three months ended March 31, 2022, compared to a loss of $12,965,247 for the same period in 2021, indicating a reduction in losses[212] - ESSA's net losses for the six months ended March 31, 2022, were $20,001,254, compared to $19,493,951 for the same period in 2021, indicating ongoing financial challenges[195] Assets and Liabilities - Total assets decreased from $198,165,818 as of September 30, 2021, to $182,609,005 as of March 31, 2022, representing a decline of approximately 7.85%[22] - Total liabilities decreased from $4,160,266 as of September 30, 2021, to $3,894,071 as of March 31, 2022, a decrease of approximately 6.4%[22] - Shareholders' equity decreased from $194,005,552 as of September 30, 2021, to $178,714,934 as of March 31, 2022, a decline of approximately 7.8%[22] - Working capital as of March 31, 2022, was $178,353,354, down from $206,202,601 a year earlier[197] - Current liabilities stood at $3,748,803 as of March 31, 2022, a decrease from $3,929,663 on September 30, 2021[217] Cash Flow - Cash and cash equivalents decreased from $137,825,024 to $86,235,830, a reduction of about 37.4%[22] - Cash used in operating activities for the six months ended March 31, 2022, was $14,204,791, compared to $11,515,058 for the same period in 2021, an increase of about 23.3%[30] - Net cash used in investing activities for the six months ended March 31, 2022, was $37,625,805, compared to $35,003,478 for the same period in 2021, an increase of approximately 7.5%[30] - Available cash reserves and short-term investments were $181,018,439 as of March 31, 2022, compared to $194,927,183 on September 30, 2021[217] Research and Development - Research and development expenses for the three months ended March 31, 2022, were $7,649,459, compared to $7,268,257 for the same period in 2021, an increase of approximately 5.2%[28] - Research and development (R&D) expenses for the six months ended March 31, 2022, totaled $13,669,218, up from $11,754,029 in the same period of 2021, reflecting ongoing clinical trials[199] - The company recognized research and development expenses of $1,113,376 for the three months ended March 31, 2022, compared to $782,846 for the same period in 2021, reflecting a 42.3% increase[79] - The company has no products in commercial production or use as of March 31, 2022[35] Clinical Trials and Product Development - The company’s investigational compound EPI-7386 is designed to disrupt the androgen receptor signaling pathway, which is crucial for prostate cancer growth[94] - The company has completed a Phase I clinical trial of its first-generation agent, ralaniten acetate (EPI-506), which showed prostate-specific antigen declines, although not sufficient for clinical benefit[95] - The Phase I clinical trial of EPI-7386 began in June 2020, with the first patient dosed in July 2020, and is currently actively enrolling patients[114] - The Phase 1 part of the clinical trial evaluates safety and tolerability to establish recommended doses for EPI-7386 and enzalutamide[192] Intellectual Property and Collaborations - The Company has developed a strong intellectual property position with 48 issued patents, including 5 covering EPI-7386, expected to provide protection until 2036 to 2041[107] - The Company retains all commercial rights for its aniten series drug portfolio and is evaluating potential collaborations to enhance the value of its prostate cancer program[141] - The Company has initiated collaborations with Janssen, Astellas, and Bayer to evaluate EPI-7386 in combination with existing antiandrogens in clinical trials[116] Future Outlook and Financial Needs - The company believes it has sufficient capital to meet its obligations for more than twelve months[217] - Future cash requirements may vary due to costs associated with preclinical work and strategic opportunities[219] - The company may need to raise additional funds in the future through strategic collaborations or share issuances[219] - There is no assurance that the company will successfully raise funds to continue its operational activities[219]

NASDAQ: EPIX O P P E NHE IMER'S 3 2 n d A N N UAL H E A LT H CA RE C O N FERENC E M A RC H 1 5- 17, 2 0 22 Forward Looking Statements 2 Certain written statements in and/or oral statements made in connection with this presentation may be considered forward-looking statements within the meaning of applicable Canadian securities laws and the United States securities laws, that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 98- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-2569713 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-2569 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-256 ...

| --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | ESSA Pharma NASDAQ: EPIX Current Non-Confidential Slide Deck March 2021 | | | | | | | | | | | | | Forward Looking Statements Certain written statements in and/or oral statements made in connection with this presentation may be considered forward-looking statements within the meaning of applicable Canadian securi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 47- ...